Stratified Stepped-Care for Reducing Suicide Attempts and Self-Harm in Youth: A Randomized Clinical Trial.

J Am Acad Child Adolesc PsychiatryDec 23, 2025 (epub)
Clinical ResearchPsychiatry

Joan R Asarnow, Greg N Clarke, Alison J Firemark et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized clinical trial evaluated whether adding stratified stepped-care for suicide prevention (SC-SP) to Zero Suicide quality improvement (ZSQI) reduced suicidal behavior among 301 youth aged 12–24 selected for recent suicidal behavior, suicidal ideation, or specified histories of suicide attempt, self-injury, and depression. At 12 months, suicide-attempt rates did not differ significantly between groups (SC-SP 8.09%; ZSQI 9.59%). Compared with ZSQI alone, SC-SP was associated with significantly less total self-harm (relative risk = 0.46, 95% CI = 0.26, 0.79, p = .006) and depression, and greater satisfaction with care.

Key findings

  • At 12 months, suicide-attempt rates were 8.09% with SC-SP and 9.59% with ZSQI, with no significant between-group difference.
  • SC-SP was associated with less total self-harm than ZSQI at 12 months (relative risk = 0.46, 95% CI = 0.26, 0.79, p = .006; number needed to treat = 10.2).
  • The SC-SP group had less depression and greater satisfaction with care than the ZSQI group at 12 months.

Why it matters

The trial distinguishes effects on suicide attempts from effects on broader self-harm outcomes: the added stepped-care program did not significantly reduce the primary outcome, but was associated with less total self-harm and depression. These findings suggest that structured, risk-matched care may improve some clinically important outcomes for youth at elevated suicide risk, while leaving its effect on suicide attempts uncertain.

What to keep in mind

The primary outcome, suicide attempts, showed no significant between-group difference. Follow-up was limited to 12 months, and no deaths were detected.

Source

Published in J Am Acad Child Adolesc Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.